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BACKGROUND: 
Obesity is associated with metabolic complications and significantly increases the risk of 
developing insulin resistance, which in turn contributes to the development of Type 2 
DM, hypertension, atherosclerosis, coronary heart disease, stroke, metabolic syndrome, 
and several types of cancer and is thus associated with an increased risk of premature 
death.  
  
 Visceral fat or visceral adipose tissue, is referred to as 'active fat which is potentially 
dangerous as it is the major player in the adverse metabolic consequences of obesity. 
In this context, one of the recently discovered and interesting adipokine that provides a 
new insight about the physiology, pathology and treatment of obesity is Vaspin. 
Vaspin is a visceral adipose tissue derived serine protease inhibitor with insulin 
sensitizing effects, belonging to the serpin superfamily, clade A (Serpin A12). 
In humans, vaspin is found to be expressed in the visceral adipose tissues in the stomach, 
liver and pancreas and also from the skin ( subcutaneous fat) and the hypothalamus. But a 
significantly higher expression was found from the visceral adipose tissues when 
compared to the subcutaneous adipose tissues. 
An increased vaspin secretion may be due to a compensatory response in order to 
antagonize the action of other unknown proteases that are up-regulated in obesity and in 
states of insulin resistance, hence this up-regulation may be a defensive and a protective 
mechanism aimed to reduce insulin resistance in humans and this protective mechanism 
of vaspin is lost with the progression to Type 2 DM and the development of 
microvascular complications. 
AIM OF THE STUDY: 
To determine the circulating Serum Vaspin levels in humans with obesity in order to 
assess its association and link to obesity related metabolic alterations. 
  
OBJECTIVES: 
1. To estimate the circulating Serum Vaspin levels in humans with obesity and in healthy 
control subjects. 
2. To estimate the anthropometric measurements (i.e the standing height & weight), the 
measures of obesity (i.e the Waist and Hip Circumference, the Waist/Hip ratio and the 
BMI) in the humans with obesity and in the healthy control subjects. 
3. To estimate the Lipid profile, the Fasting Blood Glucose levels, the Fasting serum 
insulin levels and the Insulin resistance by the HOMA-IR method in the humans with 
obesity and in the healthy control subjects. 
4. To assess and compare the Serum Vaspin levels and its correlation with the above said 
parameters in the humans with obesity and in the healthy control subjects. 
MATERIALS & METHODS: 
It is a cross sectional study consisting of thirty obese subjects in the age group of 30 to 55 
years having a BMI of ≥ 35 (Group I) and another thirty subjects of the same age group 
with a normal range BMI (Group II). 
The BMI, the measures of obesity, the fasting blood glucose levels, the lipid profile, the 
fasting serum insulin levels were obtained. The insulin resistance was estimated by the 
Homeostasis model assessment method ( HOMA – IR). Serum vaspin levels were 
  
assayed using the commercially available human vaspin ELISA kit using a human vaspin 
sandwich ELISA technique for both the study groups. 
RESULTS: 
The obese subjects (Group I ) showed significant differences in the BMI, measures of 
obesity, lipid profile, serum insulin levels, insulin resistance and the serum vaspin levels . 
(pޒ0.001). Pearson’s correlation revealed that serum vaspin levels were positively 
associated with the age, BMI, waist circumference, hip circumference HDL, LDL, TGL, 
TC/HDL ratio, LDL/HDL ratio, the fasting blood sugar levels, serum insulin levels and 
insulin resistance. 
CONCLUSION: 
From this study it can be demonstrated that vaspin may be used as a circulating biomarker 
for early identification of obesity related metabolic alterations and vaspin also plays an 
important role in the pathogenesis of obesity and its related metabolic disorders. 
KEY WORDS: 
Obesity, Diabetes mellitus, Vaspin, Insulin resistance.   
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INTRODUCTION 
 
 “LET FOOD BE THY MEDICINE AND MEDICINE BE THY FOOD” 
- Hippocrates 
                         Obesity is a chronic, multifactorial disease involving environmental, 
genetic, physiologic, metabolic, behavioural, and psychological components. It has been 
increasing at an alarming rate throughout the world to the extent that it is now a 
pandemic, affecting millions of people globally1.   
It has become the second leading and a preventable cause of death worldwide, with 
increasing rates in adults, especially in women and children2 & 38.  
 The increasing prevalence of medically significant obesity raises a great concern with an 
unequivocal trend for further increase.  
An increase in the obesity prevalence rate is evident in Westernized countries, where 
obesity has been present for decades, but today it is also particularly noticeable in the 
developing countries that previously had not experienced problems with overweight and 
obesity3. 
Globally, the prevalence of obesity is estimated to be 36.9% for men and from 38.0% for 
women4. There have been substantial increases in the prevalence of obesity in the 
developing countries as well, which is estimated to be 23.8% for men and 22.6% for 
women5. 
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India is now following a trend of other developing countries that are slowly and steadily 
becoming more obese. Obesity in India has reached epidemic proportions in the 21st 
century, with morbid obesity affecting 5% of the country's population6. 
Recent concern is focused on child and adolescent obesity, which is a rapidly growing 
problem in many countries. 
Obesity implies an excess storage of fat to an extent that it may have a negative impact on 
health37.  
The serious impact of obesity on individuals and societies throughout the world in terms 
of health, social and economic costs is the major concern. 
Obesity has been linked to a host of illnesses such as insulin resistance, Type 2 diabetes 
mellitus, hypertension, dyslipidemia, metabolic syndrome, cardiovascular diseases, liver 
diseases, breathing disorders, osteoarthritis, reproductive disorders and certain types of 
cancer7. 
These complications are caused directly due to obesity or indirectly through mechanisms 
sharing a common cause. 
Insulin resistance plays a crucial role in the pathogenesis of all these disorders and there 
are many postulated mechanisms of how an insulin resistance develops in obese 
individual 40, 41.  Obesity increases the risk of   physical as well as the mental conditions 
and as a result contributes to a 50 – 100% increased risk of death from all causes, mostly 
due to cardiovascular causes. Life expectancy of an obese individual could be shortened 
by 2 – 5 years8.   
  3  
 
The mortality rates rise as obesity increases, particularly when obesity is associated with 
an increased intra abdominal fat9. 
Abdominal obesity, also known as central obesity, is likely to have a negative impact on 
health as it is more strongly and closely related to a constellation of  
metabolic abnormalities such as insulin resistance, Type 2 diabetes mellitus, 
 dyslipidemia,  hypertension, cardiovascular diseases, Alzheimer’s  
disease as well as other metabolic, vascular and inflammatory diseases, thus serving as a 
key player in a variety of health problems10.  
In women, it is also associated with breast cancer and the need for gallbladder surgeries11. 
The prevalence of abdominal obesity is increasing in India, due to a low physical activity, 
high-calorie diets and also due to the urbanization of populations. 
Central or abdominal obesity is due to the accumulation of visceral fat or visceral adipose 
tissue which is located around the internal organs in the abdominal cavity.  
 It is also known as organ fat, truncal fat or intra abdominal fat12. Evidence that visceral 
fat tissue is more damaging to health than subcutaneous abdominal fat is rapidly 
emerging and has been reported to be detrimental to life13. It has been proposed that 
obese individuals with excess visceral obesity have a higher risk of Type 2 diabetes 
mellitus, dyslipidemia and cardiovascular diseases than those with less visceral fat 
accumulation14. 
It can also hamper confidence, making a person conscious, which may reflect on 
social interactions. 
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The potential risk factors which cause of  an abdominal obesity is due  to a decreased 
insulin sensitivity, maternal smoking, consuming estrogenic food products, hereditary, 
late night eating habits, stress, tension and other gastrointestinal problems and  is thus  
linked to  the over activity of the body's stress response mechanisms, which raise blood 
pressure, blood sugar levels, and cardiac risk15. 
Due to a dramatic rise in obesity and its metabolic sequelae, adipose tissue has gained a 
tremendous scientific interest. As it is well known that the adipose tissue is an active 
endocrine organ which serves largely as a depot for the storage of fat16.  
Apart from this important function, the adipocytes are involved in the energy metabolism 
and are the source of hormones, cytokines, and metabolites that play an important role in 
whole-body metabolism and insulin resistance17.  
These cytokines or the bioactive mediators also called the cell signalling proteins secreted 
by the visceral adipose tissue are known as adipokines or adipocytokines.  
These adipokines send signals to organs of metabolic importance including brain, liver, 
skeletal muscle, and the immune system—thereby regulating the blood pressure, 
homeostasis, lipid and glucose metabolism, inflammation, hemostasis, angiogenesis and 
atherosclerosis18. 
Currently there are about 600 known adipokines19. Some of the potential adipokines that 
are involved in the link between obesity and its related metabolic abnormalities, 
especially insulin resistance are TNF- α, IL -6, adiponectin, retinol binding protein, PAI - 
1 and leptin20.  
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The novel and the recently discovered adipokines that are also involved in the 
pathophysiology of obesity and its related metabolic disorders are vaspin, visfatin, 
resistin, omentin, chemerin etc., 21. 
Obesity is strongly associated with alterations in the physiological functions of adipose 
tissue, leading to insulin resistance, chronic inflammation, and altered secretion of 
adipokines22. An excessive accumulation of fat can cause a dysregulation of the function 
of the adipocytes thus causing an over secretion of the deleterious adipokines and a 
hyposecretion of the advantageous ones 23. 
An adipose tissue dysfunction or adisopathy plays a crucial role in the different obesity-
linked diseases including inflammation, insulin resistance and cancer 24.   
The adipose tissue that is diseased and does not function properly is called as sick fat or 
adisopathy, which results in endocrine and immune responses that would cause metabolic 
abnormalities and directly promote cardiovascular disease 25. 
The harmful effects of visceral fat are due to lipotoxicity. Unlike subcutaneous fat, 
visceral fat cells release their metabolic products directly into the portal circulation, 
which is in turn carried to the liver. These visceral fat cells that are enlarged with an 
excess of triglycerides, pour the free fatty acids into the liver causing them to accumulate 
in the pancreas, heart and other vital organs. These free fatty acids accumulate in cells, in 
various locations of the body resulting in an organ dysfunction, which produces impaired 
regulation of insulin, blood sugar, and cholesterol, as well as abnormal heart functions26. 
Faced with these risks, it's no wonder that one would want to know how much he or she 
should weigh. But this common and important question is actually the wrong question. 
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For health, the issue is not how much you weigh, but how much abdominal fat you have. 
What matters is not the body weight, but the body fat.  
The various measures of obesity include the estimation of the body mass index (BMI), 
waist & hip circumference, waist hip ratio, percentage of body fat and the skin fold 
thickness27.  
However the waist circumference is globally used as a parameter and is a simplest way to 
quantify central obesity. This is because it correlates well with excessive visceral fat, 
which appears to be the most metabolically active fat, which is responsible in causing 
insulin resistance. Therefore it is considered to be pro-atherogenic28.  
The Index of central obesity is the waist to hip ratio and is a better substitute to the waist 
circumference in defining central obesity29. 
Measures of central obesity help refine the clinical evaluation of obesity-related risk. 
 In the late 1980s and early 1990s insightful and powerful imaging techniques 
 that would further help advance the understanding of the health risks associated with 
body fat accumulation, were discovered30. Techniques such as computed 
tomography (CT) and magnetic resonance imaging (MRI) are the most accurate and have 
made it possible to categorize mass of adipose tissue located at the abdominal level into 
intra-abdominal fat and subcutaneous fat31. 
Thus a complete assessment of the risks related to adiposity appears to be as important as 
many other elements of clinical practice and is the first step toward initiating behavioural 
changes leading to weight loss. 
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One of the newly discovered adipocytokine is Vaspin (Visceral adipose tissue derived 
Serpin which was found to have insulin sensitizing effects. It is a member of serine 
protease inhibitor (SERPIN) family which was first isolated from visceral adipose tissue 
of Otsuka Long–Evans Tokushima Fatty (OLETF) rats, a model of abdominal obesity and 
type 2 diabetes32.  
In the diet induced obese OLETF rats, serum vaspin levels were found to be very high at 
the age when obesity and the plasma insulin levels reached a peak and the administration 
of vaspin to these obese rats was found to significantly improve their glucose tolerance 
and insulin sensitivity33. 
Expression of vaspin gene in visceral adipose tissue of humans and an increased 
circulating levels in the serum was found be positively associated with parameters of 
obesity, obesity related diseases, insulin resistance, and glucose metabolism 34. 
It is also indicated that vaspin plays a role in the adipoinsular axis and is associated with 
insulin resistance in obese subjects35.  
A significant correlation of vaspin with the adipokine leptin also suggests that the serum 
vaspin concentrations reflect the body fat mass in humans36. 
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Thus my study aims at estimating the serum vaspin levels in obese subjects and 
investigating the role of vaspin as a biomarker for insulin resistance and the obesity 
related metabolic alterations, by analysing the correlation between the circulating levels 
of serum vaspin in humans and the markers of insulin sensitivity, glucose and lipid 
metabolism. 
This study will focus on the regulation of insulin responsiveness by the adipokines and on 
evidence supporting the hypothesis that these adipokines play a role in the 
pathophysiology of insulin resistance. 
It will also focus upon and review the potential mechanisms by which the visceral 
adipose tissue depots are responsible in causing an insulin resistance and the other 
metabolic complications of obesity. 
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CAUSES OF OBESITY : 
Undoubtedly genes influence the susceptibility to obesity in response to specific diets and 
availability of nutrition.  
Cultural factors are also important – these relate to both availability and composition of 
the diet and to changes in the level of physical activity39.  
Obesity is attributed to a lot of behavioural features and environmental factors that affect 
diet and physical activity patterns and also there are many other secondary causes and 
factors which cause obesity42. 
 It has been established that a complex gene environment interaction determines the 
individual risk to develop obesity43.  
Many other factors such as education and socio economic status may also act as strong 
modifiers of body weight. Modern lifestyle has caused the trend towards obesity to reach 
a plateau, which supports the concept that genetic and biologic factors contribute 
substantially to the susceptibility to develop obesity 44. 
Despite the genetic predisposition it is widely accepted that the current worldwide 
epidemic of obesity is largely a consequence of dramatic changes in lifestyle and 
environment which emerged over the past 30- 50 years45.  
A dramatic change in eating habits and food selection took place, whereas physical 
activity decreased remarkably because of technological development concerning 
transportation and workplaces. A rather novel phenomenon is the expansion of fast food 
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culture characterized by high fat, low starch foods together with a high intake of sugar 
sweetened beverages which has in turn led to a body weight gain and maintenance of 
overweight and obesity in the population46. 
The secondary causes include polycystic ovarian syndrome, hypothyroidism, Cushing’s 
syndrome, hypothalamic disease and drug induced weight gain47.  
The common medications include anti diabetic agents, steroid hormones, and 
psychotropic agents, mood stabilisers, anti depressants and anti epileptic drugs48. 
Another interesting clinical observation is that an excessive weight gain during 
pregnancy, independent of the initial BMI may also increase the risk of early 
development of obesity in the offspring and thus possibly increasing the risk for other 
long term health related consequences49. 
Figure 1.Causes of obesity : 
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SUSCEPTIBILITY TO OBESITY : 
Susceptibility to obesity and its adverse consequences undoubtedly varies between 
individuals. Twin and adoption studies confirm a genetic influence on obesity. 
 The pattern of inheritance suggests a polygenic disorder, with small contributions from a 
number of different genes, together accounting for 25–70% of variation in weight.  
Recent results from ‘genome-wide’ association studies of polymorphisms in large 
numbers of people have identified a handful of genes that influence obesity, some of 
which encode proteins known to be involved in the control of appetite or metabolism and  
some of which have unknown function. However, these genes account for less than 5% of 
the variation in body weight.  
A few rare single-gene disorders have been identified that lead to severe childhood 
obesity. These include: 
 Mutations of the melanocortin-4 receptor (MC4R) 
  Defects in the enzymes processing propiomelanocortin (POMC, the precursor for 
adrenocorticotrophic hormone (ACTH) in the hypothalamus  
 Mutations in the leptin gene. 
The genetic conditions associated with obesity include: 
 Prader Willi Syndrome 
 Bardet Moon Biedel Syndrome 
 Carpenter Syndrome 
 Cohen Syndrome 
 Pseudohypoparathyroidism (Albright hereditary osteodystrophy) 
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PATHOGENESIS OF OBESITY : 
Thus obesity results from an increased energy intake, decreased energy expenditure or a 
combination of both.  
In its simplest terms, obesity can be considered to result from an imbalance between the 
amount of energy consumed in the diet and the amount of energy expended through 
exercise and bodily functions. 
 
Figure 2.Pathogenesis of Obesity: 
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PATHOLOGICAL CONSEQUENCES OF OBESITY: 
Obesity has major adverse effects on health and is associated with an increased mortality, 
with a 50 – 100% increased risk of death from all causes compared to normal weight 
individuals60. 
Obesity and overweight are the second leading causes of preventable death in the 
developing countries accounting for about 3, 00,000 deaths per year61.   
Not only the extent of excessive body fat mass, but also their anatomic location is a risk 
for metabolic and cardiovascular complications62. Mortality rates rise and the life 
expectancy is shortened as obesity increases, particularly when obesity is associated with 
intra abdominal fat63. 
In the prospective Nurses’ Health study and in the Health Professionals’ study, subjects in 
the upper normal range BMI of 23.0- 24.9kg/m²  and subjects with a BMI of  ≥ 25kg/m² 
had a four to five fold increase in developing the metabolic complications of obesity.  
And subjects with a BMI range of 29.0 – 30.9 kg/m² had a 27.6 fold higher risk of 
developing the complications64. 
It is also important to note that the duration of obesity has a strong impact on the risk of 
developing its complications. 
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An increased risk of multiple health problems associated with obesity include: 
 Insulin resistance (i.e) resistance to the effects of insulin on glucose uptake, 
metabolism and storage, characterized by a failure of target organs to respond 
normally to insulin. Insulin resistance includes a central component (incomplete 
suppression of hepatic glucose output) and a peripheral component (impaired 
insulin-mediated glucose uptake in skeletal muscle and adipose tissue)  
 Dislipidemia and Type 2 DM.  
 Hypertension, Cardiovascular diseases (such as coronary disease, stroke and 
congestive heart failure)  
 Pulmonary diseases and abnormalities (such as reduced chest wall compliance, 
increased work of breathing, increased minute ventilation, decreased functional 
residual capacity and expiratory reserve volume, obstructive sleep apnoea and 
obesity hypoventilation syndrome) 
  Degenerative joint diseases, osteoarthritis 
 Cutaneous diseases (such as acanthosis nigricans, fungal and yeast infections),   
 Reproductive disorders (such as male hypogonadism, menstrual abnormalities and 
PCOS). 
 Malignancies like the cancers of the esophagus, colon, rectum, pancreas, liver and 
prostate in males and in the females is associated with the cancers of gall bladder, 
bile ducts, breasts, endometrium, cervix and ovaries 65. 
 
    
 
Figure 3.Complications of obesity: 
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Figure 4.Risks of Cardiovascular disease and diabetes in overweight and obese 
individuals: 
 
Highlighting on the effects of insulin resistance: 
 Hyperinsulinemia and insulin resistance are ubiquitous features of obesity increasing 
with weight gain. Insulin resistance is more strongly linked to intra abdominal fat. 
 The molecular link between visceral obesity and insulin resistance in tissues such as fat, 
muscle and liver has been sought after for many years66.  
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The major factors include: 
 Insulin itself by inducing receptor down regulation 
 Free fatty acids, known to be increased and capable of impairing insulin action 
 Intracellular lipid accumulation 
 Various circulating peptides produced by adipocytes including cytokines and 
adipokines67. 
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MANAGEMENT OF OBESITY: 
The primary goal of treatment is to improve obesity related co morbid conditions and 
reduce the risk of developing future co morbidities. 
The therapy for obesity always begins with lifestyle management and may include 
pharmacotherapy or surgery depending on the BMI risk68.  
The success rates of maintenance of a long term weight loss, with lifestyle changes are 
low, ranging from 2 to 20%.  The National Institutes of Health recommends a weight loss 
goal of 5% to 10% of the person's current weight over six months69. 
LIFESTYLE MANAGEMENT:  
Obesity care involves attention to three essential elements of lifestyle: 
 Dietary habits 
 Physical activity 
 Behaviour modification70 
DIET THERAPY: 
 The primary focus of diet therapy is to reduce overall calorie consumption. The NHLBI 
guidelines recommend initiating treatment with a calorie deficit of 500 – 1000kcal/day 
compared to the patient’s habitual diet. This calorie deficit can be accomplished by 
implementing substitutions or alternatives to the diet. Examples include choosing smaller 
portions of food, eating more fruits and vegetables, consuming more whole grain cereals, 
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selecting leaner cuts of meat and skimmed dairy products, reducing fried foods and other 
added fats and oils and drinking water instead of caloric beverages. 
It is important that dietary counselling remains patient centered and that the goals are 
practical, realistic and achievable71. 
PHYSICAL ACTIVITY THERAPY:  
Although exercise alone is only moderate effective for weight loss, the combination of 
dietary modification and exercise is the most effective behavioural approach for the 
treatment of obesity. The most important role of exercise appears to be in the 
maintenance of weight loss.  
Currently the minimum public health recommendation for physical activity is 30 minutes 
of moderate intensity physical activity on most and preferably all, days of the week. 
Focusing on simple ways to add physical activity into the normal daily routine through 
leisure activities, travel and domestic work should be suggested.  
Examples include walking, using the stairs, doing home and yard work and engaging in 
sport activities72. 
The dietary guidelines for Americans 2005 summarises compelling evidence that at least 
60 - 90 minutes of daily moderate intensity physical activity is needed to sustain weight 
loss73. 
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BEHAVIOURAL THERAPY:  
Cognitive behavioural therapy is used to help change and reinforce new dietary and 
physical activity behaviours. 
 Strategies include self monitoring techniques, stress management, stimulus control, 
social support, problem solving and cognitive restructuring to help patients develop more 
positive and realistic thoughts about themselves 74.  
PHARMACOTHERAPY:  
Adjuvant pharmacological treatments should be considered for patients with a BMI ޓ 
30kg/m² who also have concomitant obesity related diseases and for whom dietary and 
physical activity therapy has not been successful.  
There are several potentials targets of pharmacologic therapy for obesity. The most 
thoroughly explored treatment is suppression of appetite via centrally active medications 
that alter monoamine neurotransmitters.  
A second strategy is to reduce the absorption of selective macronutrients from the 
gastrointestinal tract, such as fat. These two mechanisms form the basis for all currently 
prescribed anti obesity agents75. 
SURGERY:  
Bariatric surgery can be considered for patients with severe obesity (BMI ≥ 40 kg/m²) and 
those with moderate obesity (BMI ≥ 35kg/m²) associated with a serious medical 
condition. Surgical weight loss functions by reducing calorie intake and depending on the 
procedure, macronutrient absorption76
  
 
Figure 5.Surgeries for obesity: 
 
 
  
  
 
Figure 6. Bariatric Surgical procedures: 
 
 
 
A – Laproscopic Banding with the option of a reservoir band and subcutaneous acess to 
restrict the stomach further after compensatory expansion has occurred. 
B – Sleeve Gastrectomy. 
C – Roux – en – Y gastric by pass. 
D – Biliopancreatic diversions with duodenal switch. 
 
 
  
 
Figure 7.Theraupeutic options for obesity: 
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REVIEW OF LITERATURE 
MEASUREMENT OF OBESITY: 
There are various ways to measure the different aspects of obesity. They include Body 
Mass Index (BMI), skin fold thickness, waist circumference, waist to hip ratio and bio-
impedance. 
Table 1 : Methods of measuring body fat & fat distribution : 
 
BMI has traditionally been the chosen indicator to measure body size and composition, 
and to diagnose underweight and overweight individuals and is one of the most basic and 
the most common methods.  
But it is important to note that it is not a direct measure of body fat mass or distribution, 
and BMI measures may be skewed by very high muscle mass51. 
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As proposed by Trishnee Bhurosy and Rajesh Jeewon et al., ( 2013),  the BMI is a 
surrogate measure of body fatness because it is a measure of excess weight rather than 
excess body fat. This is one of the clinical limitations of BMI which has to be considered. 
Although not a direct measure of adiposity, the most widely used method to gauge 
obesity is the body mass index (BMI), which is equal to weight/ height² (in kg/m²).  
Table 2 : WHO CLASSIFICATION OF OBESITY IN THE ASIAN POPULATION 
: 
 
A BMI between 25 and 30 should be viewed as medically significant and worthy of 
therapeutic intervention, especially in the presence of risk factors that are influenced by 
adiposity, such as hypertension and glucose intolerance52. 
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Figure 8:NORMOGRAM FOR DETERMINING THE BODY MASS INDEX : 
 
However, alternative measures that reflect abdominal adiposity, such as waist 
circumference and the waist–hip ratio have been suggested as being superior to BMI in 
predicting CVD risk as proposed by Huxley et al., 201050. These are also called the field 
methods to determine central obesity. 
The circumference of the waist is widely used as a simple measure of body fatness 53.  
Adult waist circumference cut points are: 
 Increased risk of health problems: Men ≥ 94cm  & Women ≥ 80cm 
 Greatly increased risk of health problems: Men ≥ 102cm & Women ≥ 88cm 
The waist hip ratio of ޓ 0.9 in women and ޓ 1.0 in men is said to be abnormal. 
These cut off values are as proposed by the WHO expert report in December 2008. 
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Table 3: Sex specific waist circumference measurements for identification of 
individuals at increased health risk to intra abdominal fat accumulation : 
 
Table 4: Action levels to identify overweight and obese men & women with 
increased abdominal fat: 
 
An excess abdominal fat assessed by measurement of the waist circumference and waist 
hip ratio, is independently associated with higher risk for insulin resistance, diabetes 
mellitus and cardiovascular diseases and is a surrogate for visceral adipose tissue as 
documented by Yusuf et al., (2004) in the Interheart study54. 
A careful analysis of the relationship between obesity and adult‐ onset diabetes confirms 
that abdominal obesity is an important risk factor, even after controlling for age, smoking 
and family history,as the waist circumference correlates more closely with abdominal 
adipose. tissue55.
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Waist to hip ratio examines fat distribution and there are established links between waist 
circumference alone and health risk56. 
This is based largely on the rationale that increased visceral adipose tissue is associated 
with a range of metabolic abnormalities, including decreased glucose tolerance, reduced 
insulin sensitivity and adverse lipid profiles, which are risk factors for type 2 diabetes and 
CVD as documented by Huxley et al., 201057. 
Also Kiessebah et al., and Krotkiewski et al., in the 1980s demonstrated that 
hypertension, hypertriglyceridemia, hyperinsulinemia and glucose intolerance were 
increased in subjects with a high waist hip ratio.  
Gothenberg et al., in the year 2010 put forward that the waist hip ratio was a predictor of 
the future development of diabetes, myocardial infarction, angina pectoris, stroke and 
death independent of BMI58. 
Thus from the reviewed literature it has been concluded that: 
• “Waist circumference and waist–hip ratio are both related to an increased risk of 
all‐ cause mortality, throughout the range of adult BMIs”. 
• “Waist circumference and waist–hip ratio are strongly predictive in young and middle 
aged adults”. 
• “Waist circumference alone could replace waist–hip ratio and BMI as a singrisk factor 
for all‐ cause mortality”. 
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Other most accurate and sophisticated approaches to quantify an abdominal obesity 
include dual-energy X-ray absorptiometry - DEXA (under water weighing), CT or MRI 
and electrical impedance. Out of all these methods, CT and MRI scans are the imaging 
techniques to provide a direct assessment of the intra abdominal visceral adipose tissue 
and these have made it possible to precisely measure the specific adipose tissue depots59.  
Figure 9.Measurement of Hip Circumference: 
 
Figure 10.Measuring waist circumference: 
 
 
            
 
Figure 11.Measurement of skin fold thickness using skinfold callipers: 
 
Figure 12.Measuring total body fat by underwater weighing: 
 
           
 
Figure 13.Magnetic resonance imaging scanner to image 
 
Figure 14.Magnetic resonance imaging showing the visceral and subcutaneous fat 
depots: 
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OBESITY AND INSULIN RESISTANCE: 
ADIPOSE TISSUE: 
 Adipose tissue is a highly active metabolic and endocrine organ, the adipose organ that 
significantly contributes to the regulation of body's homeostasis as presented by Siiteri et 
al., 1987 and Mohamed Ali et al., 199877. Adipose tissue or fatty tissue is an 
anatomical term for loose connective tissue composed of fat cells or adipose cells called 
adipocytes. The adipose organ is a multi depot organ with a complex shape and its main 
role is to store energy in the form of lipids, although it also cushions and insulates the 
body. It also functions as a reserve of nutrients.  
The adipose tissue comprises of adipocytes, which comprise the highest percentage of 
cells within adipose tissue. There are also other cell types present which are collectively 
termed as stromal vascular fraction (SVF) of cells.  
SVF includes preadipocytes, fibroblasts, adipose tissue macrophages, and vascular 
endothelial cells78. 
Adipose tissue is derived from preadipocytes and is composed of the lipid storing adipose 
cell and a stromal/ vascular compartment in which cells including preadipocytes and 
macrophages reside.  
 The process by which adipose cells are derived from a mesenchymal preadipocyte is 
through an orchestrated series of differentiation steps mediated by a cascade of specific 
transcription factors.   
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In humans there are subcutaneous fat (adipose tissue is located beneath the skin and is 
continuous with the dermal adipose tissue) and visceral depots or the visceral fat located 
around the internal organs79. 
The key difference between these depots of fat may lie in their vascular anatomy, with the 
intra-abdominal fat draining into the portal vein and thence directly to the liver. Thus the 
adipokines that are released from adipose tissue may be at higher concentration in the 
liver and hence induce insulin resistance and promote  
Type 2 diabetes mellitus. 
Figure 15. Types of adipose tissue: 
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Adipose tissue is found in specific locations, which are referred to as adipose 
depots. There are several adipose tissue depots. - (i.e) inside the thorax (mediastinic) and 
the intra abdominal fat depots.  
 
Table 5: MAJOR ABDOMINAL DEPOTS IN HUMANS: 
 
DEPOT APPROXIMATE SIZE 
( kg) 
COMMENTS 
1.Subcutaneous : 
( anterior + posterior) 
1-20 The most variable of the 
abdominal depots 
 
2. Intra abdominal : 
  
2 a. Omental 0.5 - 3 Visceral depots; drain 
mostly to portal vein  
2 b. Mesenteric 0.5 - 2 Visceral depots; drain 
mostly to portal vein 
2 c. Perirenal 0.5 - 2 Retroperitoneal 
 
 
Of the intra abdominal depots, the most important attention and focus is to be given to the 
omental and mesenteric depots (visceral fat depots) 80.
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The colors of the organ are white and brown. The white adipose tissue is made mainly by 
white adipocytes. The brown adipose tissue is made mainly by brown adipocytes. Both 
white and brown adipose tissues are organised into a real organ, with a complex multi-
depot organisation.  
Figure 16.White and Brown Adipose tissue : 
 
White adipose, provides insulation and serves as an energy store during starvation or 
great exertion, and forms pads between organs81. When muscles and other tissues need 
energy, certain hormones bind to the adipose cells and trigger the hydrolysis 
of triacylglycerol, resulting in the release of energy-rich fatty acids and glycerol—a 
process known as lipolysis.  
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The enzyme that is responsible for hydrolysis is lipase, which is present in the blood, 
certain gastrointestinal juices, and adipose tissue. Lipase is activated by the 
hormones epinephrine, norepinephrine, glucagon, and adrenocorticotropin, which bind to 
adipocytes. 
White adipose tissue also is a source of a number of different hormones, which serve 
various roles in metabolism and endocrine function82.  
Brown adipose, found mainly in newborn animals, generates heat and actually consumes 
energy.  
In humans, the percentage of brown adipose decreases with age.  
In the animals that hibernate such as the grizzly and black bears, brown adipose tissue 
plays an important role in their survival. Species that hibernate, experience a drop in their 
body temperature and slowing of metabolism during winter dormancy, which allows 
them to conserve energy. 
 By consuming energy,the brown adipose tissue releases heat, which is vital for 
awakening and emergence from dormancy83. Brown adipose tissue is red in colour. Its 
colour and heat-generating properties are imparted by the abundance of organelles known 
as mitochondria found in brown fat cells. Mitochondria are the energy-producing 
components of cells84. 
The weight of the human adipose organ of lean adults is about 8 to 18% of body 
weight in males and 14 to 28% in females85. 
Development of the human adipose organ extends for a long period, until puberty, mainly 
through proliferation and there is an increase in size mainly during the first year.  
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The adipocyte size is correlated to the amount and the percentage of fat mass. In 
massively obese humans, the adipose organ can increase four times and reach 60 to 70% 
of body weight86. 
The adipose organ reduces its volume and size, when there is a negative energy balance. 
This reduction in size of adipocytes is important because the size of 
adipocytes correlates with insulin sensitivity87. 
Adipose mass increases by enlargement of adipose cells through lipid deposition, and also 
by an increase in the number of adipocytes. “It has been proposed that the white adipose 
tissue of humans is infiltrated with the macrophages and this level of infiltration 
correlates with body mass index and the mean size of the adipocytes”88.  
Obese adipose tissue is also characterised by increased numbers of infiltrating 
macrophages and this infiltration seems to be an important cause for the insulin resistance 
associated with obesity89. 
The distribution of adipose tissue in the different anatomic depots also has substantial 
implications for morbidity. Specifically, the intra abdominal fat has more significance 
than the subcutaneous fat and is strongly linked to the most important complications of 
obesity, such as insulin resistance, diabetes, hypertension, hyperlipidemia and 
hyperandrogenism in women. This was as proposed by Brian et al.,(2007)90. 
The mechanism underlying this association is that intra abdominal adipocytes are more 
lipolytically active than those from other depots. Release of free fatty acids into the portal 
circulation has adverse metabolic actions, especially on the liver.  
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VISCERAL ADIPOSE TISSUE AND INSULIN RESISTANCE : 
Sushter et al., in the year 2012 submitted that Asian populations have greater visceral 
adipose tissue or percentage of body fat at any given waist circumference91. 
Visceral fat is body fat that is stored within the abdominal cavity and is therefore stored 
around a number of important internal organs such as liver, pancreas and intestines. 
“Visceral fat is also known as ‘active fat’ as it plays a unique and potentially dangerous 
role in affecting how our hormones function”. 
Figure 17.Visceral Fat : 
 
Carrying a high amount of visceral fat is known to be associated with insulin resistance, 
which can lead to an increased risk of many health conditions such as  
type 2 diabetes mellitus, heart diseases, breast cancer, colorectal cancer and Alzheimer’s 
disease. Also, the hyperinsulinemia that accompanies insulin resistance would magnify 
and mediate the detrimental effects of visceral obesity92. 
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Research studies at the Harvard University in the year 2012 have noted that around 10% 
of our total fat is likely to be stored as visceral fat. Therefore if you are carrying higher 
amounts of body fat than is recommended, it is therefore more likely that you are also 
storing more visceral fat than that is healthy93. 
Although much of the details of the mechanisms by which an increased adipose tissue 
mass causes a systemic insulin resistance remains unknown, the past several years have 
witnessed an explosive increase in our understanding of what may now be referred to as 
the adipo-insulin axis.  
“There are related possibilities that insulin resistance and hyperinsulinemia, in addition to 
being caused by obesity, can also contribute to the development of obesity”94. 
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INSULIN ACTION IN ADIPOCYTE: 
Adipocytes are one of the most highly insulin-responsive cell types and insulin is a 
critical regulator of all aspects of adipocyte biology. Insulin promotes adipocyte 
triglyceride stores by a number of mechanisms, including fostering the differentiation of 
preadipocytes to adipocytes, by stimulating glucose transport, triglyceride synthesis 
(lipogenesis) and by inhibiting lipolysis .  
By stimulating lipoprotein lipase activity in adipose tissue, insulin also increases the 
uptake of fatty acids derived from circulating lipoproteins. The metabolic effects of 
insulin are mediated by a wide range of tissue-specific actions that involve rapid changes 
in protein phosphorylation and function, as well as changes in gene expression95.  
The activation of the insulin receptor tyrosine kinase, is the initial signal for the action of 
insulin and this would result in the phosphorylation of insulin receptor substrates on 
multiple tyrosine residues.  
These phospho tyrosine residues act as docking sites for many SH2 domain–containing 
proteins, including the p85 regulatory subunit of phosphoinositide 3′ kinase (PI3K). 
Binding of the p110 catalytic subunit of PI3K to p85 activates the lipid kinase that 
promotes glucose transport96. 
Insulin also activates the ras–mitogen-activated protein kinase (ras-MAPK) signaling 
cascade and this pathway appears to be important for the mitogenic effects of insulin. The 
action of insulin in the adipocytes, also involves changes in gene transcription.  
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The transcription factor ADD-1/SREBP-1c (adipocyte determination and differentiation 
factor-1/sterol regulatory element–binding protein-1c) may play a critical role in the 
actions of insulin to regulate adipocyte gene expression , by inducing genes involved in 
lipogenesis and repressing those involved in fatty acid oxidation.97   
Thus the overall action of insulin on the adipose tissue is to stimulate fat storage and 
inhibit mobilisation. 
Figure 18. Action of Insulin on Adipose tissue :  
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OBESITY AND INSULIN RESISTANCE: 
 Insulin resistance in obesity is manifested by an impaired suppression of hepatic glucose 
output and a decreased insulin-stimulated glucose transport and metabolism in the 
adipocytes and skeletal muscle.  
These functional defects are caused due to the impaired insulin signaling in all three 
target tissues and in the adipocytes. It would also result from the downregulation of 
GLUT4, which is the major insulin-responsive glucose transporter. 
In both the muscle and adipocytes, the binding of insulin to its receptor, the receptor 
phosphorylation and tyrosine kinase activity, and phosphorylation of IRSs are all reduced.  
There are also tissue-specific alterations: In the adipocytes of the obese humans, IRS-1 
expression is reduced, resulting in a decreased IRS-1–associated PI3K activity, and IRS-2 
becomes the main docking protein for PI3K. Whereas in the skeletal muscles of the obese 
individuals, IRS-1 and IRS-2 protein levels are normal but PI3K activity associated with 
both IRSs is impaired98. 
“The signaling defects in obesity may be due to an increased expression and activity of 
several protein tyrosine phosphatases (PTPs), which dephosphorylate and thus terminate 
the signals propagated through the tyrosyl phosphorylation events”99.  
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Interestingly, insulin sensitivity is present in the muscle and liver but not in the 
adipocytes. Other mechanisms also contribute to insulin resistance in obesity. In morbid 
obesity, the expressions of the molecules that signal insulin are reduced in skeletal 
muscle. 
In all forms of obesity, the downregulation of GLUT4 is a major factor contributing to the 
impaired insulin-stimulated glucose transport in adipocytes . 
 However, in the skeletal muscle of obese and diabetic individuals, GLUT4 expression is 
normal and a defective glucose transport appears to be due to an impaired translocation, 
docking, or fusion of GLUT4-containing vesicles with the plasma membrane100. 
Although insulin resistance is characteristic of obesity and type 2 diabetes, it is not 
postulated that all the actions of insulin are impaired in individuals with both these 
conditions.  There occurs an excess of lipid storage in adipose tissue and the  lipogenesis 
in the liver is increased, whereas other insulin effects related to glucose homeostasis are 
impaired.  
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REDUCED GLUCOSE DISPOSAL INTO ADIPOSE TISSUE IN OBESITY: 
 Suppression of the glucose production from the liver and an increased uptake of glucose 
into the muscle and fat, both cause insulin to lower the blood glucose levels101.  
Muscle has long been considered the major site of insulin-stimulated glucose uptake in 
vivo, with adipose tissue contributing relatively little to total body glucose disposal. This 
conclusion is supported from the fact that measurements of 2-deoxyglucose uptake in 
vivo show at least ten times more glucose per milligram of tissue going into muscle than 
into white adipose tissue (WAT) 102.  
Because muscle mass is considerably greater than WAT mass, at least in lean humans, 
this observation has been taken to indicate the prominent contribution of muscle to 
glucose disposal. The higher glucose transport into brown adipose tissue (BAT) and the 
small mass of BAT make this an unlikely site to account for large amounts of total body 
glucose uptake103.  
Thus, it is unlikely that a diminished glucose uptake into the fat cells could account for a 
diminished whole body glucose uptake in the obese individuals. Over expression of 
GLUT4 selectively in fat enhances the glucose tolerance and body’s sensitivity to insulin.  
“Knocking out GLUT4 selectively from fat, results in the development of insulin 
resistance which is similar to that seen with muscle-specific knockout of GLUT4”104.  
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Likely candidates for indirect effects are FFA, leptin, or TNF-α, all of which are known 
to affect glucose homeostasis105.  
Undoubtedly there are other undiscovered molecules that are secreted from the fat cells 
that influence the systemic metabolism. 
From studies where humans were treated with the β3 adrenergic agonist CL316,243, 
further support for a potential direct role of adipocytes in regulating systemic glucose 
homeostasis has been obtained  . Since β3 adrenergic receptors are expressed almost 
exclusively in fat, their effects would be initiated by alterations in fat106. 
 Treatment with CL316, 243 results in enhanced sensitivity of both whole body glucose 
uptake and suppression of hepatic glucose production. These effects are accompanied by 
increased glucose uptake in adipose tissue. Thus, increasing glucose uptake selectively in 
fat with β3 adrenergic receptor agonists would improve the whole body glucose uptake, 
indirectly resulting in increased insulin sensitivity in liver107.  
Alternatively, β3 agonists may work by changing the release of some products from the 
adipocytes that influences systemic insulin sensitivity108 &109. 
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THE SIGNIFICANCE OF VISCERAL FAT FOR INSULIN RESISTANCE: 
The main adverse effect of an abdominal obesity is on the action of insulin, particularly in 
the liver, muscle and adipose tissue110 & 111. 
The underlying cause of the adverse effects of an abdominal type of fat distribution is that 
intra abdominal fat cells or adipocytes exhibit a differing expression profile and are 
lipolytically more active and have got the highest rate of lipolysis. 
 This high lipolytic capacity in the visceral adipocytes is due to a greater sensitivity to 
stimulatory β - adrenoceptors and lower sensitivity to the antilipolytic α – adrenoceptors 
as well as to the receptors for other inhibitory agents such as adenosine and insulin. This 
was as proposed by Mauriege et al., 1987 and Van Harmelen at al., (1997)112.  
Thus they discharge free fatty acids, also called ‘bad actors’ at a high rate and interfere 
with the insulin sensitive glucose metabolism. They show a greater accumulation of 
macrophages and lymphocytes, indicating a greater proinflammatory activity.  
Visceral adipose tissue also has a much higher blood vessel and nerve density leading to a 
much greater metabolic activity. The venous drainage from the visceral adipose tissue 
depots drain directly into the portal vein and thus the liver is directly exposed to the its 
metabolic products such as fatty acids and proteins released from this active fat depot 
promoting insulin resistance in the liver113.  
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This would in turn increase the intraportal FFA levels and flux and an increased 
triglyceride storage, which might inhibit insulin clearance and promote insulin resistance. 
These adverse effects are called as ‘lipotoxicity’114.  
Thus the inflammatory process is detected, not only at the level of adipose tissue, but also 
affect the liver and other organs.  
As enlarged visceral fat depots are frequently associated with fat accumulation in the 
liver, it was hypothesised that secretory products from the visceral adipose tissue may 
directly cause hepatic insulin resistance. This mechanism by which insulin resistance and 
many of its deleterious effects arise due to the liberation of high rates of NEFA is called 
the Portal theory as propounded by Arner et al., 1997115. 
Thus the various potential mechanisms of how the visceral adiposity causes an insulin 
resistance are as follows: 
1. The free fatty acids and the non-esterfied fatty acids (NEFA) are the damaging 
molecules and the important products of the visceral adipocytes ( especially of the 
omental and the mesenteric adipose tissue depots) that cause insulin resistance by 
interfering with the hepatic insulin removal116.  
Thus causing a hyperinsulinemia. This was as said by Ostman et al., (1979) and 
Engfeldt & Arner et al., (1988). They also highlighted that hyperinsulinemia can 
cause an insulin resistance by down regulating the insulin receptors and desensitizing 
post receptor pathways117. 
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2. The anatomical positioning of the visceral adipose tissue depot, also plays an 
important role in the pathogenesis of insulin resistance by causing a compression 
of the viscera118 & 119. 
3. The over expression of the cytokines, genes and peptide hormones  which possess 
the capacity to influence local adipocyte biology as well as have marked effects on 
the systemic metabolism in the brain, liver, muscle, β cells, gonads, lymphoid 
organs and systemic vasculature120. 
Figure 19.Visceral fat and Insulin resistance : 
 
To summarise, chronic over nutrition with a high fat, high sugar diet and as a 
consequence an accumulation of body fat is the primary cause of chronic inflammation in 
obesity and may promote the development of systemic insulin resistance which affects 
many tissues including the liver, muscle and brain. 
          
 
Figure20:Lipotoxicity Theory of insulin resistance: 
 
Figure 21.Mechanism of how visceral adiposity causes Insulin resistance: 
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ADIPOKINES : 
Evidence for the association of obesity with inflammation dates back at least to the 1960s, 
when population studies found that obesity increases the circulating concentration of 
fibrinogen and other acute phase factors.  
The circulating concentration of more than a dozen proinflammatory cytokines such as 
tumor necrosis factor (TNF), monocyte chemoattractant protein [MCP]-1, interleukin 
[IL]-6, acute-phase reactants (C-reactive protein [CRP]), serum amyloid A [SAA]-3, 
lipocalin and procoagulant proteins plasminogen activator inhibitor [PAI]-1, Factor VII 
are now known to be increased by obesity, as reported by Hotamisligil et al., in the early 
1990s. 
Although the adipocyte has generally been regarded as an energy storage depot for fat, it 
is also an endocrine cell that releases numerous molecules in a regulated fashion. These 
include the energy balance – regulating hormone leptin, bioactive peptides called 
adipokines and cytokines such as tumour necrosis factor ( TNF α ) and interleukin ( IL – 
6 ), complement factors such as factor D ( adipsin ), prothrombotic agents such as 
plasminogen activator inhibitor I, and a component of the blood pressure regulating 
system, angiotensin.  
Lago et al in the year 2007 identified that these factors played a role in lipid 
homeostasis, insulin sensitivity, blood pressure control, coagulation and vascular health, 
insulin action, energy metabolism, inflammation, cell growth and are likely to contribute 
to obesity related pathologies121,122. 
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An excess of fat accumulation would cause the over secretion of the deleterious 
adipokines and hypo secretion of the advantageous ones. 
The visceral adipocytes secrete adipokines and cytokines which play an additional role in 
systemic complications of obesity. Thus adipokines have emerged to be a new link 
between obesity and insulin resistance. 
Table 6: Various adipokines and cytokines secreted from the visceral adipose tissue :  
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VASPIN: 
Vaspin (Visceral adipose tissue derived serpin A12 ) is an adipokine that has been 
identified as a member of serine protease inhibitor family, which is predominantly 
secreted in the visceral white adipose tissue of “Otsuka Long Evans Tokushima fatty 
(OLETF) rats”, which are an animal model of obesity and Type 2 DM123. 
Figure 22. Otsuka Long Evans Tokushima fatty ( OLETF ) rats : 
 
Vaspin is also found to be expressed in the skin, hypothalamus, pancreatic islets and 
stomach and the liver and a significantly higher expression was found from the visceral 
adipose tissues when compared to the subcutaneous adipose tissues. Human Vaspin 
protein consists of 415 amino acids and homology analysis indicate that vaspin has 
approximately about 40% identity with alpha 1 antitrypsin 124. 
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The serum vaspin levels were found to be highest at an age when obesity and the plasma 
insulin concentrations reached a peak in these OLETF rats and the levels markedly 
decreased when they developed severe hyperglycemia and the levels were normalized 
after treatment with insulin or insulin sensitizing agents like pioglitazone as studied by 
Nida et al., 2005125. 
Figure 23. Structure of vaspin :  
 
 Matthias Bluher et al in the year 2011 put forward that the serum vaspin levels were also 
found to be increased along with an increased vaspin mRNA expression in human 
adipose tissue in obese individuals with insulin resistance and type 2 DM and the lean 
human individuals had an undetectable vaspin mRNA expression 225. 
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Mechanism of action of Vaspin:  
Serpins inhibit serine proteases by a unique suicide mechanism. They contain an exposed 
reactive centre loop (RCL) that is presented to the target protease as a pseudosubstrate. 
The amino acid sequence of the RCL determines which serine protease will be inhibited 
by the serpin.  
Binding of the protease to the RCL induces conformational changes of the serpin which 
thus deforms the reactive centre of the protease and inactivates it126. 
Vaspin inhibits a protease which plays a role in the degradation of a hormone or 
molecule which has a direct or indirect glucose lowering effects. 
The increased levels of vaspin in obese individuals are due to a compensatory 
phenomenon and mechanism in response to the decreased insulin sensitivity (insulin 
resistant state) or impairment of glucose metabolism. (i.e) an increase in the vaspin 
concentrations is due to a compensatory response to antagonise the action of the other 
unknown proteases that are up regulated in obesity and in states of insulin resistance. 
Thus it serves to be a protective and defensive mechanism aimed to reduce insulin 
resistance in humans127, 128. 
Also the compensatory capacities of serum vaspin concentrations were found to decline 
with the progression of the obesity related metabolic dysfunction and thus its protective 
mechanism might be lost with the development of complications of obesity 129. 
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A central administration of vaspin to obese mice also improved their glucose tolerance, 
insulin sensitivity, affected the gene expression of candidate genes for insulin resistance 
and reduced the food intake and this favourable effect of vaspin results in bringing the 
plasma glucose levels to normal and modifying the expression of genes involved in the 
pathogenesis of insulin resistance. Thus vaspin serves as an insulin sensitizer 130. 
Thus identification of the target proteases which are inhibited by vaspin would lead to the 
development of new strategies in the treatment of obesity and would help in preventing 
the occurance of its metabolic complications. 
Human Kallikrein (hk7) has been found as the first serine protease which is inhibited by 
Vaspin. Insulin was found to be a substrate of hK7. The inhibition of hk7 by Vaspin 
prevents a hk7 mediated insulin degradation and stabilizing the circulating Insulin 
concentrations – thus improving the glycemic control in patients with Type 2 DM 131.  
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AIM & OBJECTIVES 
AIM: 
             To determine the circulating Serum Vaspin levels in humans with obesity in order 
to assess its association and link to obesity related metabolic alterations. 
OBJECTIVES: 
1. To estimate the circulating Serum Vaspin levels in humans with obesity and in healthy 
control subjects. 
2. To estimate the anthropometric measurements (i.e the standing height & weight), the 
measures of obesity (i.e the Waist and Hip Circumference, the Waist/Hip ratio and the 
BMI) in the humans with obesity and in the healthy control subjects. 
3. To estimate the Lipid profile, the Fasting Blood Glucose levels, the Fasting serum 
insulin levels and the Insulin resistance by the HOMA-IR method in the humans with 
obesity and in the healthy control subjects. 
4. To assess and compare the Serum Vaspin levels and its correlation with the above said 
parameters in the humans with obesity and in the healthy control subjects. 
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 MATERIALS AND METHODS 
 
The study was conducted during the period of June 2016 to May 2017 at the Institute of 
Physiology and Experimental Medicine, Madras Medical College, Institute of Internal 
Medicine and The Medical Endocrine Clinic, Rajiv Gandhi Government General Hospital 
after obtaining approval from Institutional Ethics Committee (IEC), Madras Medical 
College, Chennai-3. 
 
Selection of subjects:  
 
Thirty obese subjects in the age group of 30 to 55 years having a BMI of ≥ 35 (Group I ) 
and thirty subjects of the same age group with a normal range BMI ( Group II ) were 
selected from the Institute of Internal Medicine and The Medical Endocrine Clinic, Rajiv 
Gandhi Government General Hospital for the study. 
Selection of the Sample Size: 
For this study, a minimum sample size of 30 per group was required to have an 85% 
chance (alpha error 0.05). Therefore a sample size of 60 was arrived at. 
Inclusion criteria: 
Subjects in the age group of 30 to 55 years having a BMI of ≥ 35 and thirty subjects of 
the same age group with a normal range BMI were included in the study. 
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Exclusion criteria: 
Subjects with: 
1. Age ޒ 30 and ޓ 55 years 
2. BMI ޒ 35 and ޓ 45 kg/m 
3. Type I and Type II DM [according to the American Diabetes Association Criteria] 
4. Renal / Hepatic disease 
5. Acute/ Chronic Inflammatory disease [as determined by a Leukocyte count of 
ޓ7000cells/cu mm 
6. H/O hypertension [SBP < 140 mmHg and DBP < 85 mmHg] 
7. Thyroid dysfunction/PCOS and Cushing’s disease 
8. Ischemic Cardiovascular disease 
9. Alcohol or drug abuse/ Smoking 
10. Cancer 
11. Acute or Chronic infections 
12. Any haematological disorder 
13. Hormonal therapy 
14. Chronic Medication therapies (such as on antidepressants, anticonvulsants, 
hypoglycaemic drugs, anti hypertensives, lipid lowering agents, OCPs and 
corticosteroids) 
15. Pregnancy 
16. Any chronic medical or psychiatric illness 
 
STUDY DESIGN: Cross Sectional Study  
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PLACE OF STUDY:  
1. Institute of Physiology & Experimental Medicine,  
            Madras Medical College, Chennai-3.  
2. Institute of  Internal Medicine,  
           Rajiv Gandhi Government General Hospital, Ch-3. 
3. Medical Endocrine clinic 
Rajiv Gandhi Government General Hospital, Ch-3. 
Methodology: 
Thirty obese subjects in the age group of 30 to 55 years having a BMI of ≥ 35 (Group I) 
and thirty subjects of the same age group with a normal range BMI (Group II) 
participated in the study. 
After obtaining an informed consent and before inclusion in the study, a detailed history 
was obtained from all the study subjects and they also underwent a careful and through 
physical examination and  laboratory investigations to exclude any condition that might 
interfere with the study parameters. 
The following were obtained and measured for all the study subjects using standard 
protocols: 
1. The anthropometric measurements ( i.e) the standing height and weight in light 
clothing without shoes were obtained using a stretch resistant measuring tape and 
the BMI was calculated using the formula wt (kg) / Ht (m2). 
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2. The measures of obesity (i.e) the waist circumference, the hip circumference were 
obtained and the waist hip ratio was calculated. 
According to the WHO Stepwise Approach to surveillance (STEPS) protocol, the 
measurement for the waist circumference was made at the approximate midpoint between 
the lower margin of the last palpable rib and the top of the iliac crest at the end of a 
normal expiration. The measurement was made with a stretch resistant measuring tape 
that provides a constant 100gm of tension, with the tape parallel to the floor. 
According to the WHO Stepwise Approach to surveillance (STEPS) protocol, the 
measurement for the hip circumference was taken around the widest portion of the 
buttocks. 
It was ensured that the subject was standing erect with relaxed abdominal muscles, the 
arms by the side, feet positioned close together and the weight evenly distributed across 
the feet and the clothing removed from the waistline. The measurement was made with a 
stretch resistant measuring tape that provides a constant 100gm of tension, with the tape 
parallel to the floor. 
3. After an overnight fast, between 8 and 10 am a blood sample was taken and serum 
collected and stored at - 80°C. 
4. The fasting blood glucose levels, the lipid profile (total cholesterol, triglycerides, 
HDL cholesterol, LDL cholesterol), the fasting serum insulin levels were obtained. 
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5. The insulin resistance was estimated by the Homeostasis model assessment 
method (HOMA – IR) by using the formula fasting insulin (µIU/L) x fasting 
glucose (mg/dL)/405. 
 
6. Serum vaspin levels were assayed using the commercially available human vaspin 
ELISA kit using a human vaspin sandwich ELISA technique. 
The sample handling, storage and preparation were done according to the manufacturer’s 
instructions. 
The serum vaspin levels of the obese subjects were compared and correlated with the 
subjects who had a normal BMI. 
ESTIMATION OF THE FASTING BLOOD SUGAR LEVELS: 
Sample Collection and Storage: 
 Under aseptic precautions about 5ml of a fasting blood sample was collected from 
the subject and was centrifuged and serum separated. 
 The serum samples were stored at -20 degrees Celsius. 
 Roche Diagnostics Cobas GLU HK Gen.3 kit which contains an in vitro diagnostic 
reagent system was used for estimating the serum fasting blood glucose levels by 
the Electrochemiluminescence method. The test was done at the Central lab, 
Institute of Biochemistry, Madras Medical College, Chennai. 
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Principle of the test: 
 In electro generated chemiluminescence, electrochemically generated 
intermediates undergo a highly exergonic reaction to produce an electronically 
excited state that then emits light. 
 It is an enzymatic reference method with hexokinase. 
 Hexokinase catalyzes the phosphorylation of glucose to glucose-6-phosphate by 
ATP. 
 In the presence of NADP, Glucose-6-phosphate dehydrogenase oxidizes glucose-
6-phosphate to gluconate-6-phosphate. No other carbohydrate 
           is oxidized. The rate of NADPH formation during the reaction is directly 
           proportional to the glucose concentration and is measured   
           photometrically. 
 Reagents Required: 
 R1: MES buffer: 5.0 mmol/L, pH 6.0; Mg2+: 24 mmol/L; ATP: ≥ 4.5 mmol/L; 
NADP: ≥ 7.0 mmol/L; preservative. 
 R2:HEPES buffer: 200 mmol/L, pH 8.0; Mg2+: 4 mmol/L; HK (yeast): 
≥ 300 μkat/L; G-6-PDH (E. coli): ≥ 300 μkat/L; preservative. 
Assay Procedure: 
After calibration and controls had been measured, the test samples were loaded on to the 
Cobas Analyser and the desired test was ordered in the host computer system. The 
samples were evaluated for the fasting blood glucose levels and when the analysis was 
complete, the results were automatically obtained. 
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ESTIMATION OF FASTING LIPID PROFILE LEVELS: 
Sample Collection and Storage: 
 Under aseptic precautions about 5ml of a fasting blood sample was collected from 
the subject and was centrifuged and serum separated. 
 The serum samples were stored at -20 degrees Celsius. 
 Roche Diagnostics Cobas CHOL Gen.2, HDLC Gen.3 and TRIGL kits were used 
for estimating the serum total cholesterol, HDL and triglycerides by the 
Electrochemiluminescence method. The test was done at the Central lab, Institute 
of Biochemistry, Madras Medical College, Chennai. 
Principle of the test: 
For estimation of Total Cholesterol: 
 In electro generated chemiluminescence, the intermediates which are 
electrochemiccaly generated undergo an exergonic reaction and produce an 
electronically excited state that emits light.  
 It is an enzymatic, colorimetric method. 
 Cholesterol esters are cleaved by the action of cholesterol esterase to yield free 
cholesterol and fatty acids.  
 Cholesterol oxidase catalyzes the oxidation of cholesterol to cholest-4-en-3-one 
and hydrogen peroxide. 
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 In the presence of peroxidase, the hydrogen peroxide formed effects the oxidative 
coupling of phenol and 4-aminophenazone to form a red  
quinone-imine dye. 
 The cholesterol concentration is directly proportional to the colour intensity of the 
dye that is formed and this is determined by measuring the increase in absorbance. 
 
For the estimation of HDL: 
 In electrogenerated chemiluminescence, The intermediates undergo a highly 
exergonic reaction in order to produce an electronically excited state that then 
emits light. 
 It is a homogeneous enzymatic colorimetric test. 
 In the presence of magnesium ions, dextran sulfate selectively forms 
          water-soluble complexes with LDL, VLDL and chylomicrons which 
          are resistant to PEG-modified enzymes.  
 The HDL-cholesterol concentartion is determined by cholesterol esterase and 
cholesterol oxidase coupled with PEG to the amino groups enzymatically. (approx. 
40 %). 
 Cholesterol esters are broken down quantitatively into free cholesterol 
and fatty acids by cholesterol esterase. 
 In the presence of oxygen, cholesterol oxidase oxidises cholesterol to  
Δ4-cholestenone and hydrogen peroxide. 
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 In the presence of peroxidase, the hydrogen peroxide generated reacts 
          with 4-amino-antipyrine and HSDA to form a purple-blue dye, whose colour   
          intensity is directly proportional to the cholesterol concentration. This  is then  
          measured photoelectrically. 
For the estimation of triglycerides: 
 In electrogenerated chemiluminescence, intermediates undergo an exergonic 
reaction in order to produce an electronically excited state that then emits light. 
 It is an enzymatic colorimetric test. 
 This method is based on the work by Wahlefeld using a lipoprotein lipase 
          from microorganisms for the rapid and complete hydrolysis of triglycerides 
          to glycerol followed by oxidation to dihydroxyacetone phosphate and  
          hydrogen peroxide.  
 Under the catalytic action of peroxidise, the hydrogen peroxide produced then 
reacts with 4-aminophenazone and 4-chlorophenol to form a red dyestuff (Trinder 
endpoint reaction).  
 The color intensity of the red dye stuff formed is directly proportional to  
          the triglyceride concentration and can be measured photometrically. 
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Reagents Required: 
For the estimation of Total Cholesterol: 
 R1 : PIPES buffer: 225 mmol/L, pH 6.8; Mg2+: 10 mmol/L; sodium cholate:0.6 
mmol/L; 4-aminophenazone: ≥ 0.45 mmol/L; phenol: ≥ 12.6 mmol/L;fatty alcohol 
polyglycol ether: 3 %; cholesterol esterase (Pseudomonasspec.): ≥ 25 μkat/L (≥ 1.5 
U/mL); cholesterol oxidase (E. coli): ≥ 7.5 μkat/L(≥ 0.45 U/mL); peroxidase 
(horseradish): ≥ 12.5 μkat/L (≥ 0.75 U/mL);stabilizers; preservative. 
For the estimation of HDL: 
 R 1: HEPES buffer: 10.07 mmol/L; CHES 96.95 mmol/L, pH 7.4; dextransulfate: 
1.5 g/L; magnesium nitrate hexahydrate: > 11.7 mmol/L; HSDA: 0.96 mmol/L; 
ascorbate oxidase (Eupenicillium sp., recombinant):> 50 μkat/L; peroxidase 
(horseradish): > 16.7 μkat/L; preservative. 
 R2: HEPES buffer: 10.07 mmol/L, pH 7.0; PEG-cholesterol esterase 
(Pseudonomas spec.): > 3.33 μkat/L; PEG-cholesterol oxidase (Streptomyces sp., 
recombinant): > 127 μkat/L; peroxidase (horseradish): > 333 μkat/L; 4-amino-
antipyrine: 2.46 mmol/L; preservative. 
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For the estimation of triglycerides: 
 R1: PIPES buffer: 50 mmol/L, pH 6.8; Mg2+: 40 mmol/L; sodium cholate:0.20 
mmol/L; ATP: ≥ 1.4 mmol/L; 4-aminophenazone: ≥ 0.13 mmol/L;4-chlorophenol: 
4.7 mmol/L; lipoprotein lipase (Pseudomonas spec.):≥ 83 μkat/L; glycerokinase 
(Bacillus stearothermophilus): ≥ 3 μkat/L;glycerol phosphate oxidase (E. coli): ≥ 
41 μkat/L; peroxidase (horseradish):≥ 1.6 μkat/L; preservative. 
Assay Procedure: 
After calibration and controls had been measured, the test samples were loaded on to the 
Cobas Analyser and the desired test was ordered in the host computer system. The 
samples were evaluated for the fasting lipid profile and when the analysis was complete, 
the results were automatically obtained. 
 
Estimation of the fasting Serum Insulin Levels: 
Sample Collection and Storage: 
 Under aseptic precautions about 5ml of a fasting blood sample was collected from 
the subject and was centrifuged and serum separated. 
 The serum samples were stored at -20 degrees Celsius. 
 Roche Diagnostics Insulin kit was used for estimating the serum fasting Insulin 
levels by the Electrochemiluminescence method. The test was done at the Central 
lab, Institute of Biochemistry, Madras Medical College, Chennai. 
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Test Principle: 
 Sandwich principle. Total duration of assay: 18 minutes. 
 1st incubation: Insulin from 20 μL sample, a biotinylated monoclonal 
           insulin‑ specific antibody, and a monoclonal insulin‑ specific antibody 
           labeled with a ruthenium complex form a sandwich complex. 
 2nd incubation: The complex becomes bound to the solid phase via interaction of 
biotin and streptavidin after addition of streptavidin-coated microparticles,  . 
 The reaction mixture obtained is then aspirated into the measuring cell where the 
microparticles are magnetically captured onto the surface of the 
          electrode. Unbound substances are then removed with 
          ProCell/ProCell M. Application of a voltage to the electrode then induces 
          chemiluminescent emission which is measured by a photomultiplier. 
 Results are determined via a calibration curve. This is instrument specifically 
generated by 2‑ point calibration and a master curve provided 
via the reagent barcode. 
Reagents Required: 
 M Streptavidin-coated microparticles (transparent cap), 1 bottle, 6.5 mL: 
          Streptavidin-coated microparticles 0.72 mg/mL; preservative. 
 R1 Anti-insulin-Ab~biotin (gray cap), 1 bottle, 10 mL: 
          Biotinylated monoclonal anti‑ insulin antibody (mouse) 1 mg/L; MESb) 
          buffer 50 mmol/L, pH 6.0; preservative. 
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 R2 Anti-insulin-Ab~Ru(bpy) (black cap), 1 bottle, 10 mL: 
           Monoclonal anti‑ insulin antibody (mouse) labeled with ruthenium 
complex 1.75 mg/L; MES buffer 50 mmol/L, pH 6.0; preservative. 
Assay Procedure: 
After calibration and controls had been measured, the test samples were loaded on to the 
Cobas Analyser and the desired test was ordered in the host computer system. The 
samples were evaluated for the fasting serum insulin levels and when the analysis was 
complete, the results were automatically obtained. 
Estimation of Serum Vaspin Levels: 
Sample Collection and Storage: 
 Under aseptic precautions about 5ml of a fasting blood sample was collected from 
the subject and was centrifuged and serum separated. 
 The serum samples were stored at -20 degrees Celsius. 
 Elabscience Vaspin Elisa kit was used for estimating the serum fasting blood 
glucose levels by the Electrochemiluminescence method. The test was done at the 
Central lab, Institute of Biochemistry, Madras Medical College, Chennai. 
Test Principle: 
This ELISA kit uses Sandwich-ELISA as the method. The micro ELISA plate provided in 
this kit has been pre-coated with an antibody specific to VASPIN. Standards or samples 
are added to the appropriate micro ELISA plate wells and combined with the specific 
antibody.  
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Then an antibody specific for VASPIN and Avidin-Horseradish Peroxidase (HRP) 
conjugate is added to each micro plate well successively and incubated. Free components 
are washed away. The substrate solution is added to each well. Only those wells that 
contain VASPIN, biotinylated detection antibody and Avidin-HRP conjugate will appear 
blue in color. The enzyme-substrate reaction is terminated by the addition of a sulphuric 
acid solution and the color turns yellow. The optical density (OD) is measured spectro 
photometrically at a wavelength of 450 nm ± 2 nm. The OD value is proportional to the 
concentration of VASPIN. You can calculate the concentration of VASPIN in the 
samples by comparing the OD of the samples to the standard curve. 
 
Reagents Required: 
1. Reference Standard 
2. Reference Standard & Sample Diluent 
3. Concentrated Biotinylated Detection Ab 
4. Biotinylated Detection Ab Diluent 
5. Concentrated HRP Conjugate 
6. HRP Conjugate Diluent 
7. Concentrated Wash Buffer 
8. Substrate Reagent 
9. Stop solution 
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Other Materials Required: 
1. Micro Elisa Plate 
2. Microplate reader with 450nm wavelength filter  
3. High-precision transferpettor, EP tubes and disposable pipette tips 
4. 37℃ Incubator  
5. Deionized or distilled water 
6. Absorbent paper 
7. Loading slot for Wash Buffer 
8. Plate Sealer 
Assay Procedure: 
All reagents and samples were brought to room temperature before use. The sample was 
centrifuged again after thawing before the assay.  
All the reagents were mixed thoroughly before pipetting and it was taken care that 
foaming was avoided.   
1. 100μLof Standard and Samples were added to each well. The blank well was added 
with Reference Standard & Sample diluent. Solutions were added to the bottom of micro 
ELISA plate well and were mixed gently and the plate was covered with sealer and was 
incubated for 90 minutes at 37℃. 
2. The liquid of each well was removed and 100μL of Biotinylated Detection Ab working 
solution was added to each well. It was then covered with the Plate sealer which was then 
incubated for 1 hour at 37°C.   
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3. Each well was aspirated and washed, and this process was repeated three times. Then 
wash was done by filling each well with Wash Buffer (approximately 350μL) Complete 
removal of liquid at each step was ensured. After the last wash, the remaining Wash 
Buffer was removed by aspirating and the plate was inverted and patted against thick 
clean absorbent paper.  
4. 100μL of HRP Conjugate working solution was added to each well and covered with 
the Plate sealer which was then incubated for 30 minutes at 37°C.  
5. The wash process was repeated for five times as conducted in step 3.  
6. 90μL of Substrate Solution was added to each well and covered with a new Plate sealer 
which was then incubated for about 15 minutes at 37°C. When apparent gradient 
appeared in standard wells, the reaction was terminated. 
7. 50μLof Stop Solution was added to each well and the colour turned yellow 
immediately.  
Using a micro-plate reader set to 450 nm, the optical density of each well was 
determined. 
Calculation of Results: 
Absorbance (Optical density) values of standard controls and samples were calculated. 
With concentration on X axis and absorbance value on Y axis, 
plotting the mean absorbance got from each standard against its concentration, a 
standard curve was constructed. Using this standard curve based on mean 
absorbance value, corresponding concentration of each sample was found. 
The data was analyzed, using the IBM SPSS software version 22.  
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Normal Values: 
Fasting Blood sugar – 70 to 110 mg/dl 
Total cholesterol ޒ 200mg/dl 
HDL – 35.3 to 79.5 mg/dl 
LDL ޒ 100mg/dl 
TGL – 40 to 160mg/dl 
Serum Insulin – 2 to 25 µIU/mL 
HOMA – IR – ޒ 3 
The minimum detectable range of Serum Vaspin using the Elabscience Vaspin Elisa kit is 
0.0625 to 4 ng/ml. 
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RESULTS 
A total of 60 subjects were included in the study. 
Table 7: Descriptive analysis of Gender in Group I (obese subjects) (N = 30): 
 
Gender Frequency Percentage 
Male 5 16.66% 
Female 25 83.33% 
 
Table 8: Descriptive analysis of Gender in Group II (Non - obese subjects)  
(N = 30): 
 
Gender Frequency Percentage 
Male 3 10% 
Female 27 90% 
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Table 9 : Descriptive measurements of the study participants: 
VARIABLES GROUP I (Obese subjects) 
Mean ± SD 
GROUP II ( Non – Obese) 
Mean ± SD 
BMI 40.59± 3.98 22.87± 1.81 
Waist Circumference 
(cms) 
115± 9.13 83.23± 1.54 
Hip 
Circumference(cms) 
127.47± 10.75 104.60± 3.45 
W/H Ratio 0.95± 0.073 0.79± 0.02 
FBS ( mg/dl) 90.6 ± 18.123 62.07 ± 15.04 
TC (mg/dl) 186.23 ± 51.54 145.27 ± 33.77 
HDL (mg/dl) 44.9 ± 1.98 47.5 ± 2.78 
TGL (mg/dl) 136.8 ± 43.21 106.07 ± 70.21 
TC/HDL Ratio 4.89 ± 1.86 4 ± 1.33 
LDL/HDL Ratio 3.02 ± 1.58 2 ± 0.87 
Serum Insulin 
(µIU/mL) 
29.21 ± 20.17 11.05 ± 6.53 
Insulin Resistance 6.60 ± 4.41 1.81 ± 1.59 
Serum Vaspin 
(ng/ml) 
1.26 ± 1.18 0.73± 0.59  
 
The statistical analysis of the data was performed using the IBM SPSS software version 
22.The Mean and Standard deviation of the variables were determined for the two study 
groups.  The Unpaired student t test was employed as the Test of significance at 95% 
confidence interval. 
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* P value < 0.05 was considered as statistically significant 
** P value < 0.01 was considered as highly statistically significant 
***P value < 0.001 was considered as very highly statistically significant 
TABLE 10 
COMPARISON OF THE BMI BETWEEN THE TWO STUDY GROUPS 
 
VARIABLES STUDY 
GROUPS 
MEAN SD P Value 
BMI 
(kg/m²) 
GROUP I 40.59 3.98 0.0001*** 
GROUP II 22.87 1.81 
Table No.10 compares the age and BMI of the two study groups. The P values of the age 
and BMI were very highly significant. 
Graph 1: COMPARISON OF THE BMI BETWEEN THE TWO STUDY GROUPS 
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TABLE 11 
COMPARISON OF THE MEASURES OF OBESITY (WAIST 
CIRCUMFERENCE, HIP CIRCUMFERENCE AND WAIST HIP RATIO) 
BETWEEN THE TWO STUDY GROUPS 
VARIABLES STUDY 
GROUPS 
MEAN SD P Value 
WAIST 
CIRCUMFERENCE 
(cms) 
GROUP I 115.5 9.13 0.0001*** 
GROUP II 83.23 1.54 
HIP 
CIRCUMFERENCE 
(cms) 
GROUP I 127.47 10.75 0.0001*** 
GROUP II 104.60 3.45 
WAIST/ HIP 
RATIO 
GROUP I 0.95 0.073 0.0001*** 
GROUP II 0.79 0.02 
 
Table No.11 compares the waist circumference, hip circumference and the waist/ hip ratio 
between the two study groups. 
The P values of waist circumference, the hip circumference and the waist/hip ratio were 
very highly significant. 
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Graph 2: COMPARISON OF THE MEASURES OF OBESITY (WAIST 
CIRCUMFERENCE, HIP CIRCUMFERENCE AND WAIST HIP RATIO) 
BETWEEN THE TWO STUDY GROUPS 
 
TABLE 12 
COMPARISON OF THE SERUM FASTING BLOOD SUGAR LEVELS 
BETWEEN THE TWO STUDY GROUPS 
VARIABLES STUDY 
GROUPS 
MEAN SD P Value 
SERUM FBS 
(mg/dl)  
GROUP I 90.6 18.12 0.0001*** 
GROUP II 62.07 15.04 
 
Table No.12 compares the serum fasting blood sugar levels between the two study groups 
.The P value of the serum fasting blood sugar levels was very highly significant. 
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Graph 3: COMPARISON OF THE SERUM FASTING BLOOD SUGAR LEVELS 
BETWEEN THE TWO STUDY GROUPS 
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TABLE 13 
COMPARISON OF THE FASTING LIPID PROFILE BETWEEN THE TWO 
STUDY GROUPS 
VARIABLES STUDY 
GROUPS 
MEAN SD P Value 
TOTAL 
CHOLESTEROL 
(mg/dl) 
GROUP I 186.23 51.54 0.0006*** 
GROUP II 145.27 33.77 
HDL 
(mg/dl) 
GROUP I 44.9 1.98 0.0001*** 
GROUP II 47.5 2.78 
LDL 
(mg/dl) 
GROUP I 115 48.16 0.0175* 
GROUP II 90.63 25.63 
TGL 
(mg/dl) 
GROUP I 136.8 43.21 0.0457* 
GROUP II 106.07 70.21 
TC/HDL GROUP I 4.89 1.86 0.0373* 
GROUP II 4 1.33 
LDL/HDL GROUP I 3.02 1.58 0.0030** 
GROUP II 2 0.87 
Table No.13 compares the fasting lipid profile between the two study groups. 
The P values of total cholesterol and HDL were very highly significant. 
The P values of LDL, triglycerides and TC/HDL ratio were significant. 
The P value of LDL/HDL ratio was highly significant. 
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Graph 4: COMPARISON OF THE FASTING LIPID PROFILE BETWEEN THE 
TWO STUDY GROUP 
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Table No.14 compares the Serum fasting insulin levels and Insulin resistance of the two 
study groups.  
The P values of the Serum fasting insulin levels and Insulin resistance were very highly 
significant. 
 
Graph 5: COMPARISON OF THE SERUM FASTING INSULIN LEVELS AND 
INSULIN RESISTANCE BETWEEN THE TWO STUDY GROUPS 
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TABLE 15 
COMPARISON OF THE SERUM VASPIN LEVELS BETWEEN THE TWO 
STUDY GROUPS 
VARIABLES STUDY 
GROUPS 
MEAN SD P Value 
SERUM 
VASPIN 
(ng/ml)  
GROUP I 1.26 1.18 0.0318* 
GROUP II 0.73 0.59 
 
Table No.15 compares the serum vaspin levels between the two study groups. 
The P value of the serum vaspin was statistically significant. 
Graph 6: COMPARISON OF THE SERUM VASPIN LEVELS BETWEEN THE 
TWO STUDY GROUPS 
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Table 16 
CORRELATION OF SERUM VASPIN LEVELS WITH THE AGE AND BMI  
VARIABLE AGE ( YEARS) BMI ( kg/m²) 
 r             
     VASPIN              
                                    P              
0.115 
 
 
0.54 
0.722 
 
 
0.00001*** 
 
Table 17 
CORRELATION OF SERUM VASPIN LEVELS WITH THE WAIST 
CIRCUMFERENCE, HIP CIRCUMFERENCE AND WAIST HIP RATIO  
VARIABLE WC (cms) HC (cms) W/H RATIO 
                          r 
VASPIN 
                          P 
0.6140 0.5775 -0.0815 
0.0003*** 0.0008*** 0.67 
 
Table 18 
CORRELATION OF SERUM VASPIN LEVELS WITH THE SERUM FASTING 
BLOOD SUGAR LEVELS  
VARIABLE FBS (mg/dl) 
                                R 
VASPIN 
                                 P 
0.0802 
0.767 
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Table 19 
CORRELATION OF SERUM VASPIN LEVELS WITH THE LIPID PROFILE  
VARIABLE TC(mg/dl) HDL(mg/dl) LDL(mg/dl) TGL TC/HDL LDL/HDL 
                r 
VASPIN  P 
-0.245 -0.35 0.254 0.0708 0.004 0.052 
0.19 0.168 0.174 0.7 0.97 0.78 
 
Table 20 
CORRELATION OF SERUM VASPIN LEVELS WITH THE FASTING SERUM 
INSULIN LEVELS AND INSULIN RESISTANCE  
VARIABLE SERUM INSULIN  
( µIU/ml) 
INSULIN RESISTANCE 
                  R 
VASPIN                P 
0.070 0.139 
0.595 0.289 
 
Pearson’s correlation revealed that serum vaspin levels were positively associated with 
the age, BMI, waist circumference, hip circumference HDL, LDL, TGL, TC/HDL ratio, 
LDL/HDL ratio, the fasting blood sugar levels, serum insulin levels and insulin 
resistance. 
The serum vaspin levels were negatively correlated with the waist hip ratio, fasting blood 
sugar and total cholesterol levels. 
(** Pearson’s correlation is significant at the level P ޒ 0.05)  
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DISCUSSION 
Obesity is a common chronic disorder of excessive body fat and has become a global 
epidemic which is prevalent in the industrialised, developing and in the underdeveloped 
countries. 
 Obesity increases the risk of developing a variety of adverse consequences to human 
health ranging from metabolic disturbances including type 2 Diabetes Mellitus and 
cardiovascular complications to disorders of the locomotor system and many types of 
cancer132.  
Increased visceral adiposity is usually associated with a clustering of atherogenic risk 
factors and it plays a central role in insulin resistance and its related metabolic alterations. 
Adipokines form a new exciting link between obesity and insulin resistance133. 
In the current study, the purpose was to estimate and investigate the role of vaspin as a 
novel potential biomarker of insulin resistance in the obese subjects. This was with the 
view that serum vaspin levels could be used as an early identification of the obesity and 
its related metabolic alterations, which would in turn enable us to make early 
interventions to protect oneself from its ruinous complications. 
In my study, the BMI, measures of obesity, the lipid profile, serum insulin levels, the 
insulin resistance and the serum vaspin levels were estimated and compared in both the 
obese and the non obese subjects.  
And the serum vaspin levels were also correlated with the measures of obesity and the 
insulin resistance in both the obese and the non obese subjects. 
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In this study, the obese subjects showed an elevated BMI when compared to the non 
obese subjects. The vaspin levels also showed a significant positive correlation with their 
BMI values. 
This means that the vaspin concentration increases with an increase in BMI. 
The results presented here are in line with Youn et al., (2008)134 and Esaki et al., 
(2009)135 who observed a significant BMI adjusted correlation with vaspin. 
Regarding the measures of obesity, the waist circumference, the hip circumference and 
the waist hip ratio were found to be elevated in the obese subjects when compared to the 
non obese subjects with a normal range BMI. 
And the waist circumference of both the obese and the non obese subjects showed a 
significant positive correlation with their serum vaspin levels. This result is in accordance 
to Scott M Grundy et al., (2013)136 who proposed that the waist circumference is a 
globally used parameter to quantify central obesity and is the key culprit in insulin 
resistance and its related complications. Thus it can be proposed that greater the waist 
circumference of an individual, greater would be the serum vaspin levels. This finding in 
my study is to be highlighted as it suggests that a higher serum vaspin levels in the obese 
individuals is an indicator of visceral obesity and its related complications.  
Looking at the lipid profile in this study, the total cholesterol, the serum triglyceride 
levels and the LDL cholesterol showed a significant elevation in the obese subjects when 
compared to the non obese subjects. The TGL levels and the HDL cholesterol levels, 
LDL cholesterol levels and the cardiovascular risk assessment ratios showed a positive 
with the serum vaspin levels. 
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These results agree with El-Mesallamy et al.,(2011)137 who demonstrated that vaspin 
levels are significantly correlated with markers of lipid metabolism such as TGL and to a 
lesser extent LDL cholesterol, indicating that vaspin may play a role in lipid metabolism 
or might be induced as a compensatory response by dyslipidemia in visceral obesity. This 
is especially because vaspin is an adipokine secreted by adipocytes.  
This observation is also in accordance with Pascot et al., (2001)138 and Boudenwijri 
Klop et al., (2013)139 who reported that hypertriglyceridemia and the dyslipidemic state 
(characterised by an increased fasting triglycerides, high LDL cholesterol, low HDL 
cholesterol, elevated blood glucose and insulin levels) found in subjects with a visceral 
obesity was an independent and a key contributing factor in increasing the risk for 
cardiovascular disorders. 
Thus this positive association suggests that increased serum Vaspin levels in obese 
individuals increases their risk of acquiring a cardiovascular disease. 
Furthermore evaluating the CVD risk assessment ratios, TC/HDL- C and  
LDL- C/HDL- C, a significant difference was found in the obese and the non obese 
subjects. 
This study also demonstrated that the serum vaspin levels and the insulin resistance of the 
obese subjects were significantly elevated when compared to the non obese subjects. 
And the serum insulin levels and the insulin resistance in both the obese and the non 
obese subjects showed a positive correlation with their serum vaspin levels. 
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These results suggest that the obese subjects with a high serum vaspin levels may be 
prone to develop the obesity related metabolic complications in the future. 
It was postulated that an increase in the serum vaspin levels in the obese individuals was 
due to an increased secretion of the adipokine vaspin from the visceral adipose tissues 
and represented a compensatory mechanism or a response associated with obesity in 
order to antagonize the action of the other unknown proteases that are up regulated in 
obesity and in states of insulin resistance. Hence this up regulation is said to be a 
defensive mechanism against insulin resistance (Hida et al., 2005 ; Kloting et al., 2006; 
Zvonic et al., 2007)140,141& 142. 
In addition the results showed that there is a positive correlation between age and vaspin 
concentration in the obese subjects.  
These results are in agreement with Youn et al.,(2008)143 who reported that age is an 
independent predictor of vaspin concentration in obese subjects. 
There is also a positive correlation of the fasting blood sugar levels and the serum vaspin 
levels in the obese subjects. 
These results are in agreement with El-Mesallamy et al.,(2011)144 who found that serum 
vaspin levels were significantly correlated with the markers of insulin resistance and the 
glycemic indices suggesting that vaspin level may play a role in glucose metabolism and 
may be a part of the protective mechanisms aimed to reduce insulin resistance in humans. 
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CONCLUSION 
The conclusions derived from the present study are: 
 Vaspin, a visceral adipose tissue derived factor with potential antiprotease 
properties and insulin sensitising effects is increased in obesity. 
 Vaspin levels are positively correlated and associated with the BMI, the measures 
of obesity and insulin resistance in the form of HOMA –IR. 
 Vaspin could be used as a biomarker in obesity and as an indicator of 
cardiovascular risk. 
 Vaspin also plays an important role in the pathogenesis of obesity and its related 
metabolic disorders. 
 Hence Vaspin can also be used as a circulating biomarker for early identification of 
obesity related metabolic alterations and thus can enable us to make interventions at 
the earliest.
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SUMMARY 
A study was conducted to determine the circulating Serum Vaspin levels in humans 
with obesity in order to assess its association and link to obesity related metabolic 
alterations. 
Thirty obese subjects and thirty non obese subjects participated in the study. 
The serum vaspin levels, the measures of obesity, the lipid profile and the insulin 
resistance was obtained, assessed and compared in both the study groups and the 
results showed a significant increase in the values of the parameters in the obese 
subjects than in the non obese subjects. 
The serum vaspin levels were correlated with the above said parameters in obese 
subjects and a significant positive correlation was also obtained between them. 
Thus the association and the link of vaspin to obesity and its related metabolic 
complication were established and can be used as a maker in obesity. 
The study population in this study is relatively small and there are an unequal number 
of gender representatives. The correlation between the gender and the vaspin levels 
has not been made as there are more women subjects in my study. 
Use of a larger sample size and an equal number of gender representatives and also 
gold standard methods as an indicator of obesity and insulin resistance would help get 
a clearer picture of the role of vaspin as a biomarker of obesity and its related 
metabolic alterations. 
This would be my suggestion for future studies in this field. 
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INFORMED CONSENT FORM 
Title of the study: “Estimation of the serum Vaspin levels in humans with obesity 
as a novel circulating and therapeutic biomarker for obesity and its related 
metabolic alterations” 
Name of the Participant:                                                                                                    
Name of the Principal Investigator: Dr. THAMIZH VALLI.D                                        
Name of the Institution:                                                                                                                   
Institute of Physiology and Experimental Medicine,                                                           
Madras Medical College and Govt. General Hospital,                                                     
Chennai – 3. 
Documentation of the informed consent:                                                                              
I _____________________________ have read the information in this form (or it has 
been read to me). I was free to ask any questions and they have been answered. I am 
over 18 years of age and, exercising my free power of choice, hereby give my consent 
to be included as a participant in : 
“Estimation of the serum Vaspin levels in humans with obesity as a novel 
circulating and therapeutic biomarker for obesity and its related metabolic 
alterations” 
1. I have read and understood this consent form and the information provided to me.  
2. I have had the consent document explained to me.                                                       
3. I have been explained about the nature of the study.                                                    
4. I have been explained about my rights and responsibilities by the investigator.        
5. I have been informed the investigator of all the treatments I am taking or have taken 
in the past ________ months including any native (alternative) treatment.                   
6. I have been advised about the risks associated with my participation in this study.  
7. I agree to cooperate with the investigator and I will inform him/her immediately if I 
suffer unusual symptoms.                                                                                                      
8. I have not participated in any research study within the past________month(s).      
9. I am aware of the fact that I can opt out of the study at any time without having to 
give any reason and this will not affect my future treatment in this hospital.              
10. I am also aware that the investigator may terminate my participation in the study at 
any time, for any reason, without my consent.                                                              
11. I hereby give permission to the investigators to release the information obtained 
from me as result of participation in this study to the sponsors, regulatory authorities, 
Govt. agencies, and IEC. I understand that they are publicly presented.                     
12. I have understood that my identity will be kept confidential if my data are publicly 
presented.                                                                                                                      
13. I have had my questions answered to my satisfaction.                                                 
14. I have decided to be in the research study. 
  
 
I am aware that if I have any question during this study, I should contact the 
investigator. By signing this consent form I attest that the information given in this 
document has been clearly explained to me and understood by me, I will be given a 
copy of this consent document. 
 
 
Name and signature / thumb impression of the participant (or legal 
representative if participant incompetent) 
 
Name _________________________ Signature_________________  
 
Date_____________ 
  
 
Name and Signature of the investigator or his representative obtaining consent: 
 
Name _________________________ Signature_________________  
 
Date________________ 
 
 
 
 
 
 
 
 
  
 
PATIENT PROFORMA 
Name: 
Age/ Sex: 
Address: 
OP No.:   
Occupation: 
History of diabetes mellitus:        
History of Hypertension: 
History of associated illness: 
a. Thyroid disorders & cancers 
b. Renal & hepatic diseases 
c. Swellings in & around the neck region 
History of smoking and alcohol abuse: 
History of taking chronic medications or hormonal therapies: 
Investigations: 
EXAMINATION: 
General Physical examination: 
Anthropometric measurements: 
 
Ht: 
Wt:  
WC: 
HC: 
W/H Ratio: 
  
 
Vitals: 
Pulse rate:   
Blood pressure: 
Respiratory Rate: 
 Temperature: 
 
Systemic examination: 
Cardiovascular system: 
 
Respiratory system: 
 
Gastrointestinal system: 
 
 
Central nervous system 
 
 
 
 
 
  
 
 
 
 
 
MASTER CHARTS 
  
 
S.NO AGE BMI 
Waist 
Circumference 
(cms) 
Hip 
circumference 
 ( Cms) 
Waist/ 
Hip 
Ratio 
FBS  
( mg/dl) 
Sr.Insulin 
(µIu/L) 
HOMA- 
IR 
TC 
(mg/dl) 
HDL  
(mg/dl) 
LDL 
(mg/dl) 
TGL 
(mg/dl) 
LDL/HDL 
Ratio 
TC/HDL 
Ratio 
VASPIN   
( ng/ml) 
1 36 48 125 140 0.9 75 9.79 1.81 195 49 124 109 2.53 4 0.541 
2 36 38 125 137 0.91 73 13.35 2.4 207 35 139 163 3.97 5.9 0.038 
3 50 39 130 145 0.89 81 28.42 5.68 191 34 120 184 3.53 5.6 0.539 
4 50 47.3 120 137 0.88 111 45.05 12.34 212 38 146 139 3.84 5.6 3.585 
5 35 36 102 115 0.88 98 34.13 8.25 225 58 121 231 2.09 3.9 2.024 
6 37 45 135 150 0.9 90 25.23 5.6 163 34 95 170 2.79 4.8 0.265 
7 35 37 104 115 0.9 88 28.34 6.15 231 39 163 143 4.18 5.9 1.639 
8 45 39.2 128 140 0.91 66 101.7 16.5 168 30 108 151 3.60 5.6 1.122 
9 50 42.1 119 135 0.88 118 22.01 6.41 185 38 118 146 3.11 4.9 0.867 
10 50 45 130 145 0.89 95 38.17 8.95 228 45 164 94 3.64 5.1 1.453 
11 36 42 130 140 0.92 100 26.05 6.43 221 42 164 75 3.90 5.3 0.216 
12 50 38 113 125 0.9 95 14.8 3.47 171 44 101 129 2.30 3.9 1.894 
13 50 37 116 120 9.96 87 19.54 4.19 199 59 119 104 2.02 3.4 0.779 
14 45 51 119 134 0.88 87 10.18 2.18 346 64 252 148 3.94 5.4 2.975 
15 50 45 121 135 0.89 138 19.6 6.67 270 27 194 243 7.19 10 1.487 
BASELINE CHARACTERISTICS – OBESE 
SUBJECTS 
  
 
S.NO AGE BMI 
Waist 
Circumference 
(cms) 
Hip 
circumference  
( Cms) 
Waist/ 
Hip 
Ratio 
FBS  
( mg/dl) 
Sr.Insulin 
(µIu/L) 
HOMA- 
IR 
TC 
(mg/dl) 
HDL  
(mg/dl) 
LDL 
(mg/dl) 
TGL 
(mg/dl) 
LDL/HDL 
Ratio 
TC/HDL 
Ratio 
VASPIN   
( ng/ml) 
16 45 37 102 115 0.88 92 11.52 2.61 220 37 157 132 4.24 5.9 2.397 
17 40 40 112 125 0.89 86 27.49 5.83 161 29 93 194 3.21 5.6 1.184 
18 37 42 112 120 0.93 69 29.65 5.05 243 22 176 225 8.00 11 0.072 
19 35 38 110 125 0.88 76 13.28 2.49 182 35 119 138 3.40 5.2 3.585 
20 40 38 115 130 0.88 101 20.2 5.03 168 41 104 117 2.54 4.1 3.585 
21 45 40 109 120 0.9 95 17.61 4.13 144 39 83 110 2.13 3.7 0.319 
22 35 41 116 130 0.89 72 19.27 3.42 148 38 88 108 2.32 3.9 0.065 
23 40 37 105 115 0.91 118 28.77 8.38 146 35 87 120 2.49 4.2 0.2 
24 45 42 104 117 0.88 86 13.52 2.87 156 54 82 100 1.52 2.9 0.469 
25 40 46 110 124 0.88 92 31.23 7.09 157 48 87 108 1.81 3.3 1.108 
26 50 38 110 115 0.95 44 11.5 1.24 127 42 70 74 1.67 3 0.537 
27 35 38 110 115 0.95 79 29.09 5.67 205 35 35 122 1.00 5.9 0.664 
28 35 37 111 120 0.92 102 62.3 15.69 106 37 47 109 1.27 2.9 3.585 
29 35 37 111 120 0.92 102 62.3 15.69 106 37 47 109 1.27 2.9 0.145 
30 35 37 111 120 0.92 102 62.3 15.69 106 37 47 109 1.27 2.9 0.319 
  
 
S.NO AGE BMI 
Waist 
Circumference 
(cms) 
 
Hip 
circumference 
 ( Cms) 
Waist/ 
Hip 
Ratio 
FBS  
( mg/dl) 
Sr.Insulin 
(µIu/L) 
HOMA- 
IR 
TC 
(mg/dl) 
HDL  
(mg/dl) 
LDL 
(mg/dl) 
TGL 
(mg/dl) 
LDL/HDL 
Ratio 
TC/HDL 
Ratio 
VASPIN   
( ng/ml) 
1 35 24 82 102 0.8 37 12.07 1.10 128 26 77 123 3.0 4.9 0.361 
2 30 24 82 105 0.78 50 5.63 0.70 219 24 108 435 4.5 9.1 0.689 
3 35 20 83 105 0.79 73 4.52 0.81 145 43 82 98 1.9 3.4 1.592 
4 35 21 83 107 0.77 67 8.87 1.47 175 44 110 105 2.5 4 0.921 
5 36 24 82 105 0.78 66 10.27 1.67 178 32 127 94 4.0 5.6 0.532 
6 37 22 83 105 0.79 61 6.54 0.99 147 47 77 117 1.6 3.1 .42 
7 37 24 84 105 0.8 94 37.7 8.75 109 32 63 69 2.0 3.4 0.386 
8 38 24 84 107 0.78 63 15.63 2.43 194 30 127 185 4.2 6.5 0.301 
9 35 21 83 110 0.75 57 10.96 1.54 153 28 107 91 3.8 5.5 0.642 
10 36 23 81 110 0.73 71 6.87 1.20 116 39 64 64 1.6 3 0.71 
11 36 24 82 100 0.82 56 7.29 1.01 158 41 99 90 2.4 3.9 0.71 
12 39 24 82 100 0.82 73 10.92 1.97 203 56 128 94 2.3 3.6 1.323 
13 40 22 82 110 0.75 67 13.44 2.22 133 42 75 78 1.8 3.2 0.529 
14 35 18 83 100 0.83 66 12.03 1.96 177 49 108 100 2.2 3.6 0.881 
15 37 20 84 100 0.84 68 7.69 1.29 157 44 101 59 2.3 3.6 1.662 
BASELINE CHARACTERISTICS – NON OBESE 
  
 
S.NO AGE BMI 
Waist 
Circumference 
(cms) 
Hip 
circumference 
 ( Cms) 
Waist/ 
Hip 
Ratio 
FBS  
( mg/dl) 
Sr.Insulin 
(µIu/L) 
HOMA- 
IR 
TC 
(mg/dl) 
HDL  
(mg/dl) 
LDL 
(mg/dl) 
TGL 
(mg/dl) 
LDL/HDL 
Ratio 
TC/HDL 
Ratio 
VASPIN   
( ng/ml) 
16 37 25 84 100 0.84 80 10.07 1.99 167 42 100 123 2.4 4 0.058 
17 35 25 83 105 0.79 74 11.59 2.12 169 28 93 238 3.3 6 1.509 
18 35 25 83 105 0.79 64 7.25 1.15 201 31 141 146 4.5 6.5 0.693 
19 37 25 82 102 0.8 53 8.14 1.07 221 52 139 151 2.7 4.3 1.167 
20 38 21 82 102 0.8 53 13.37 1.75 151 40 91 101 2.3 3.8 0.258 
21 40 22 82 102 0.8 39 4.34 0.42 245 63 155 134 2.5 3.9 0.693 
22 37 25 83 105 0.79 53 9.26 1.21 133 45 64 122 1.4 3 0.129 
23 35 21 83 105 0.79 17 10.22 0.43 127 36 65 131 1.8 3.5 0.012 
24 50 24 86 109 0.78 55 14.47 1.97 142 33 75 171 2.3 4.3 0.71 
25 39 21 86 109 0.78 54 8.89 1.19 186 43 117 129 2.7 4.3 0.471 
26 38 24 87 109 0.79 62 5.72 0.88 130 42 72 82 1.7 3.1 1.623 
27 35 23 82 100 0.82 60 10.77 1.60 155 32 108 76 3.4 4.8 1.911 
28 37 24 82 100 0.82 64 4.91 0.78 159 34 108 86 3.2 4.7 3.97 
29 39 23 86 107 0.8 87 20.68 4.44 163 33 104 130 3.2 4.9 0.027 
30 
37 23 86 107 0.8 78 21.28 4.10 217 51 134 160 2.6 4.3 0.13 
  
 
KEY TO MASTER CHART 
BMI – Body Mass Index 
FBS – Fasting Blood Sugar 
HOMA – IR – Homeostatic model assessment- Insulin resistance 
TC – Total Cholesterol 
HDL – High density lipoprotein 
TGL – Triglycerides 
LDL – Low Density Lipoprotein 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
